New antibiotics for selective treatment of gastrointestinal infection caused by Clostridium difficile

Bibliography

• Blondeau JM. What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea? J Antimicrob Chemother 2009;63:238-42
   PubMed Web of Science ®Google Scholar
• Wilcox MH, Mooney L, Bendall R, A case–control study of community-associated Clostridium difficile infection. J Antimicrob Chemother 2008;62:388-96
   PubMed Web of Science ®Google Scholar
• Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes. J Infect 2009;58:403-10
   PubMed Web of Science ®Google Scholar
• Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol 1997;92:739-50
   PubMed Web of Science ®Google Scholar
• Tenover FC, McDonald LC. Vancomycin-resistant staphylococci and enterococci: epidemiology and control. Curr Opin Infect Dis 2005;18:300-5
   PubMed Web of Science ®Google Scholar
• Baines SD, O'Connor R, Freeman J, Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008;62:1046-52
   PubMed Web of Science ®Google Scholar
• Johnson AP. OPT-80, a narrow-spectrum macrocyclic antibiotic. Curr Opin Invest Drugs 2007;8:168-73
   PubMed Web of Science ®Google Scholar
• Ackermann G, Loffler B, Adler D, In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother 2004;48:2280-82
   PubMed Web of Science ®Google Scholar
• Credito KL, Appelbaum PC. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob Agents Chemother 2004;48:4430-34
   PubMed Web of Science ®Google Scholar
• Finegold SM, Molitoris D, Vaisanen ML, In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother 2004;48:4898-902
   PubMed Web of Science ®Google Scholar
• Hecht DW, Galang MA, Sambol SP, In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007;51:2716-19
   PubMed Web of Science ®Google Scholar
• Karlowski JA, Laing NM, Zhanel GG. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrob Agents Chemother 2008;52:4163-65
   Google Scholar
• Citron DM, Babakhani F, Goldstein EJC, Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection. Anaerobe 2009;15:234-36
   PubMed Web of Science ®Google Scholar
• Goldstein E, Citron D, Sears P, Comparative fidaxomicin susceptibilities of isolates collected at baseline, failure and recurrence from patients in a phase III trial of Clostridium difficile infection (CDI). Presented at 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) [Presentation L1-1641]; 12 – 15 September 2009; San Francisco, CA, USA
   Google Scholar
• Babakhani F, Robert N, Shangle S, Antimicrobial activity and post-antibiotic effect (PAE) of OPT-80, a new macrocyclic compound, against Clostridium difficile. Presented at 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) [Presentation E-2048]; 30 October – 2 November 2004; Washington, DC, USA
   Google Scholar
• Swanson RN, Hardy DJ, Shipkowitz NL, In vitro and in vivo evaluation of Tiacumicins B and C against Clostridium difficile. Antimicrob Agents Chemother 1991;35:1108-11
   PubMed Web of Science ®Google Scholar
• Shue YK, Sears PS, Shangle S, Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Chemother 2008;52:1391-95
   PubMed Web of Science ®Google Scholar
• Louie T, Miller M, Donskey C, Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother 2009;53:223-28
   PubMed Web of Science ®Google Scholar
• Miller MA, Mullane KM, Weiss K, Faster time to resolution of diarrhea with fidaxomicin vs. vancomycin in patients with Clostridium difficile infection. Presented at 47th IDSA Annual Meeting; 29 October – 1 November 2009 [Presentation 422]; Philladelphia, PA, USA
   Google Scholar
• Mullane KM, Miller MA, Weiss K, Effect of concomitant antibiotics on treatment of Clostridium difficile (CDI) infection with fidaxomicin or vancomycin. Presented at 47th IDSA Annual Meeting [Presentation LB-14]; 29 October – 1 November 2009; Philladelphia, PA, USA
   Google Scholar
• Golan Y, Mullane K, Miller M, Low recurrence rate among patients (pts) with C. difficile Infection (CDI) treated with fidaxomicin (FDX). Presented at 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) [Presentation L1-1639]; 12 – 15 September 2009; San Francisco, CA, USA
   Google Scholar
• Gorbach S, Weiss K, Sears P, Safety of fidaxomicin versus vancomycin in treatment of Clostridium difficile infection. Presented at 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) [Presentation L1-1640]; 12 – 15 September 2009; San Francisco, CA, USA
   Google Scholar
• Sears P, Louie T, Mullane K, Pharmacokinetics/pharmacodynamics (PK/PD) of fidaxomicin in treatment of Clostridium difficile infection (CDI). Presented at 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) [Presentation A1-1949]; 12 – 15 September 2009; San Francisco, CA, USA
   Google Scholar
• Crook D, Weiss K, Comely O, Randomized clinical trial (RCT) in Clostridium difficile infection (CDI) confirms equivalent cure rate and lower recurrence rate of fidaxomicn (FDX) versus vancomycin (VCN). Presented at 20th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) [Poster LB2401]; 10 – 13 April 2010; Vienna, Austria
   Google Scholar
• Johnson S, Crook D, Comely O, Randomized clinical trial (RCT) in Clostridium difficile infection (CDI) confirms superiority of fidaxomicin over vancomycin. Presented at digestive disease week [Presentation 828630]; 1 – 5 May 2010; New Orleans, LA, USA
   Google Scholar
• Optimer Pharmaceuticals Reports Positive Data from its North American Phase 3 CDI Study of OPT-80. Available from: http://www.optimerpharma.com/news.asp?news_story=69&page_num=&year=2008
   Google Scholar
• Optimer Pharmaceuticals Announces Positive Results from Second Fidaxomicin Phase 3 Study in Patients with Clostridium Difficile Infection. Available from: http://www.optimerpharma.com/news.asp?news_story=106&page_ num=&year=2010
   Google Scholar
• Okumu F, Walsh RB, Sears P, Safety and pharmacokinetics of OPT-80, a novel antibiotic for treatment of Clostridium difficile associated diarrhea (CDAD). Presented at 44th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) [Presentation F726]; 30 October – 2 November 2004; Wachington, DC, USA
   Google Scholar
• Critchley IA, Green LS, Young CL, Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections. J Antimicrob Chemother 2009;63:954-63
   PubMed Web of Science ®Google Scholar
• Citron DM, Warren YA, Tyrrell KL, Comparative in vitro activity of REP3123 against Clostridium difficile and other anaerobic intestinal bacteria. J Antimicrob Chemother 2009;63:972-76
   PubMed Web of Science ®Google Scholar
• Ochsner UA, Bell SJ, O'Leary AL, Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model. J Antimicrob Chemother 2009;63:964-71
   PubMed Web of Science ®Google Scholar
• Moeck G, Draghi DC, Arhinn FF, In vitro activity profile of oritavancin against a broad spectrum of aerobic and anaerobic bacterial pathogens. Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) [Presentation E-1612]; 12 – 15 September 2007; Chicago, IL, USA
   Google Scholar
• O'Connor R, Baines S, Freeman J, In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin. J Antimicrob Chemother 2008;62:762-5
   PubMed Web of Science ®Google Scholar
• Baines SD, O'Connor R, Saxton K, Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype O27 infection in a human gut model. J Antimicrob Chemother 2008;62:1078-85
   PubMed Web of Science ®Google Scholar
• Targanta Therapeutics. Targanta announces launch of oral oritavancin development program against C. difficile bacterial infection. Available from: http://media.integratir.com/targ/PressReleases/TARG%20C%20Diff%20Program%20042108.pdf
   Google Scholar
• Wadman SN, Appleyard AN, Ayala T, NVB302: a narrow spectrum antibiotic under development for the treatment of clostridium difficile infection. Presented at 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) [Presentation F1-1517]; 12 – 15 September 2009; San Francisco, CA, USA
   Google Scholar
• Baines SD, Huscroft GS, Todhunter SL, NVB302: In vitro activity against Clostridium difficile. Presented at 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) [Presentation F1-1519]; 12 – 15 September 2009; San Francisco, CA, USA
   Google Scholar
• Wadman SN, Citron DM, Choi S, NVB302: in vitro activity against Clostridium difficile and intestinal strains of anaerobic bacteria. Presented at 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) [Presentation F1-1518]; 12 – 15 September 2009; San Francisco, CA, USA
   Google Scholar
• Wadman SN, Appleyard AN, Candiani G, NVB302: gastro-intestinal stability and in vivo activity in the hamster cecitis model for Clostridium difficile infection. Presented at 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) [Presentation F1-1520]; 12 – 15 September 2009; San Francisco, CA, USA
   Google Scholar
• Product pipeline. Novacta Therapeutics. Available from: http://www.novactabio.com/page.php?id=38&phpMyAdmin=vb0ih1-JSrS5dbIFQ3BcdGuaAF7 [Last accessed 11 May 2010]
   Google Scholar
• Dubreuil L, Houcke I, Mouton Y, In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob Agents Chemother 1996;40:2266-70
   PubMed Web of Science ®Google Scholar
• McVay CS, Rolfe RD. In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob Agents Chemother 2000;44:2254-8
   PubMed Web of Science ®Google Scholar
• Hecht DW, Galang MA, Sambol SP, In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007;51:2716-19
   PubMed Web of Science ®Google Scholar
• Freeman J, Bains SD, Todhunter SL, Nitazoxanide is active against epidemic Clostridium difficile strains with reduced susceptibility to metronidazole. Presented at 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) [Presentation E-1476]; 12 – 15 September 2009; San Francisco, CA, USA
   Google Scholar
• Hoffman PS, Sisson G, Croxen MA, Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni. Antimicrob Agents Chemother 2007;51:868-76
   PubMed Web of Science ®Google Scholar
• Musher DM, Logan N, Hamill RJ, Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006;43:421-7
   PubMed Web of Science ®Google Scholar
• Musher DM, Logan N, Mehendiratta V, Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother 2007;59:705-10
   PubMed Web of Science ®Google Scholar
• Musher DM, Logan N, Bressier AM, Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 2009;48:e41-46
   PubMed Web of Science ®Google Scholar
• Jarvis WR, Schlosser J, Jarvis AA, National point prevalence of Clostridium difficile in US health care facility inpatients, 2008. Am J Infect Control 2009;37:263-70
   PubMed Web of Science ®Google Scholar
• Song X, Bartlett JG, Speck K, Rising economic impact of Clostridium difficile-associated disease in adult hospitalized patient population. Infect Control Hosp Epidemiol 2008;29:823-28
   PubMed Web of Science ®Google Scholar
• Press release: cardiovascular systems, Inc. acquires replidyne, Inc. Available from: http://www.dealipedia.com/deal_view_acquisition.php?r=13893 [Last accessed 14 May 2010]
   Google Scholar
• Crestone. Available from: http://www.crestonepharma.com [Last accessed 6 July 2010]
   Google Scholar
• National Institutes of Health. Available from: http://www.clinicaltrials.gov/ct2/results?term=Optimer [Last accessed 16 May 2010]
   Google Scholar
• Optimer product pipeline. Available from: http://www.optimerpharma.com/pipeline.asp?pipeline=1 [Last accessed 16 May 2010]
   Google Scholar
• Optimer. Antibiotic macrocycle compounds and methods of manufacture and use thereof. WO2009070779; 2009
   Google Scholar
• Optimer. Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof. WO2008091554; 2008
   Google Scholar
• Optimer. Compositions of stable tiacumicins. WO2008091518; 2008
   Google Scholar
• Optimer. Method of treating Clostridium difficile-associated diarrhea. WO2007048059; 2007
   Google Scholar
• Optimer. 18-membered macrocycles and analogs thereof. WO2006085838; 2006
   Google Scholar
• Novacta. Lantibiotic-based compounds having antimicrobial activity. WO2009010765; 2009
   Google Scholar
• Novacta. The use of type-b lantibiotic-based compounds having antimicrobial activity. WO2009010763; 2009
   Google Scholar
• Targanta. Methods of treatment using single doses of oritavancin. WO2010025438; 2010
   Google Scholar
• Targanta. Method of inhibiting clostridium difficile by administration of oritavancin. WO2009036121; 2009
   Google Scholar
• Replidyne. 2-NH-Heteroarylimidazoles are inhibitors of bacterial methionyl tRNA synthetase and are of use in treating bacterial infections. WO2004052288; 2004
   Google Scholar